PE20120315A1 - A PHARMACEUTICAL COMPOSITION INCLUDING CANDESARTAN, CANDESARTAN CILEXETIL, OR AZILSARTAN, COMBINED WITH AMLODIPINE - Google Patents

A PHARMACEUTICAL COMPOSITION INCLUDING CANDESARTAN, CANDESARTAN CILEXETIL, OR AZILSARTAN, COMBINED WITH AMLODIPINE

Info

Publication number
PE20120315A1
PE20120315A1 PE2011001882A PE2011001882A PE20120315A1 PE 20120315 A1 PE20120315 A1 PE 20120315A1 PE 2011001882 A PE2011001882 A PE 2011001882A PE 2011001882 A PE2011001882 A PE 2011001882A PE 20120315 A1 PE20120315 A1 PE 20120315A1
Authority
PE
Peru
Prior art keywords
esprotonous
benzimidazole
biphenyl
methyl
candesartan
Prior art date
Application number
PE2011001882A
Other languages
Spanish (es)
Inventor
Wataru Hoshina
Makoto Fukuta
Shigeyuki Marunaka
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43032637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120315(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20120315A1 publication Critical patent/PE20120315A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA SOLIDA QUE COMPRENDE: A) UN COMPUESTO BENZIMIDAZOL DE FORMULA (I) DONDE R1 ES UN GRUPO HETEROCICLICO QUE CONTIENE NITROGENO MONOCICLICO Y UN ATOMO DE HIDROGENO DESPROTONABLE, R2 ES CARBOXILO OPCIONALMENTE ESTERIFICADO, Y R3 ES ALQUILO INFERIOR OPCIONALMENTE SUSTITUIDO; SIENDO COMPUESTOS PREFERIDOS: 1-(CICLOHEXILOXICARBONILOXI)ETIL 2-ETOXI-1-[[2'-(1H-TETRAZOL-5-IL)BIFENIL-4-IL]METIL]BENZIMIDAZOL-7-CARBOXILATO, 2-ETOXI-1-[[2'-(1H-TETRAZOL-5-IL)BIFENIL-4-IL]METIL]-1H-BENZIMIDAZOL-7-CARBOXILICO, ACIDO 2-ETOXI-1-[[2'-(4,5-DIHIDRO-5-OXO-1,2,4-OXADIAZOL-3-IL)BIFENIL-4-IL]METIL]-1H-BENZIMIDAZOL-7-CARBOXILICO; B) UN ALCOHOL DE AZUCAR TAL COMO MANITOL, SORBITOL O ERITRITOL; C) UN ANTAGONISTA DE CALCIO TAL COMO AMLODIPINA, AZELNIDIPINA, ARANIDIPINA, ENTRE OTROS; Y D) POLIETILENO GLICOL DE PESO MOLECULAR DE 1.000 A 10.000. DICHA COMPOSICION PRESENTA UNA MEJOR ESTABILIDAD DEL DERIVADO BENZIMIDAZOL SIENDO UTIL EN EL TRATAMIENTO DE LA HIPERTENSIONIT REFERS TO A SOLID PHARMACEUTICAL COMPOSITION THAT INCLUDES: A) A BENZIMIDAZOLE COMPOUND OF FORMULA (I) WHERE R1 IS A HETEROCYCLIC GROUP CONTAINING MONOCYCLIC NITROGEN AND AN ATOMO OF HYDROGEN, AND A SUBSTITUTE INFANT-PROTITLE OPYLUM-OPYLUMOUS RETROGEN, R2 ESPROTONOUS, ESPROTONOUS, SUBSTICIOUS RICHALMENTAL, R2 ESPROTONOUS, ESPROTONOUS, SUBSTICIOUS RICHARDO, R2, ESPROTONOUS, SUBSTITUOUS RICHARDO, R2 ; BEING PREFERRED COMPOUNDS: 1- (CYCLOHEXYLOXYCARBONYLOXY) ETHYL 2-ETOXY-1 - [[2 '- (1H-TETRAZOL-5-IL) BIPHENYL-4-IL] METHYL] BENZIMIDAZOLE-7-CARBOXYLATE, 2-ETOXY-1- [[2 '- (1H-TETRAZOLE-5-IL) BIPHENYL-4-IL] METHYL] -1H-BENZIMIDAZOL-7-CARBOXYL, 2-ETHOXY-1 ACID - [[2' - (4,5-DIHYDRO- 5-OXO-1,2,4-OXADIAZOL-3-IL) BIPHENYL-4-IL] METHYL] -1H-BENZIMIDAZOLE-7-CARBOXYL; B) A SUGAR ALCOHOL SUCH AS MANNITOL, SORBITOL OR ERYTHRITOL; C) A CALCIUM ANTAGONIST SUCH AS AMLODIPINE, AZELNIDIPINE, ARANIDIPINE, AMONG OTHERS; AND D) POLYETHYLENE GLYCOL OF MOLECULAR WEIGHT OF 1,000 TO 10,000. SUCH COMPOSITION PRESENTS A BETTER STABILITY OF THE BENZIMIDAZOLE DERIVATIVE BEING USEFUL IN THE TREATMENT OF HYPERTENSION

PE2011001882A 2009-04-30 2010-04-28 A PHARMACEUTICAL COMPOSITION INCLUDING CANDESARTAN, CANDESARTAN CILEXETIL, OR AZILSARTAN, COMBINED WITH AMLODIPINE PE20120315A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009111381 2009-04-30
JP2010068625 2010-03-24

Publications (1)

Publication Number Publication Date
PE20120315A1 true PE20120315A1 (en) 2012-04-07

Family

ID=43032637

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001882A PE20120315A1 (en) 2009-04-30 2010-04-28 A PHARMACEUTICAL COMPOSITION INCLUDING CANDESARTAN, CANDESARTAN CILEXETIL, OR AZILSARTAN, COMBINED WITH AMLODIPINE

Country Status (24)

Country Link
EP (1) EP2424501A2 (en)
JP (1) JP5666471B2 (en)
KR (1) KR101797776B1 (en)
CN (1) CN102481248B (en)
AU (1) AU2010242308A1 (en)
BR (1) BRPI1014388A2 (en)
CA (1) CA2760073A1 (en)
CL (1) CL2011002662A1 (en)
CO (1) CO6470841A2 (en)
CR (1) CR20110581A (en)
DO (1) DOP2011000329A (en)
EA (1) EA201171329A1 (en)
EC (1) ECSP11011494A (en)
GE (1) GEP20135940B (en)
IL (1) IL215962A0 (en)
MA (1) MA33280B1 (en)
MX (1) MX2011011011A (en)
MY (1) MY158158A (en)
NZ (1) NZ596395A (en)
PE (1) PE20120315A1 (en)
SG (1) SG175794A1 (en)
TW (1) TWI438201B (en)
WO (1) WO2010126168A2 (en)
ZA (1) ZA201108375B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL236001B1 (en) 2012-12-21 2020-11-30 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Complex pharmaceutical composition comprising candesartan cilexetil and amlodipine, its preparation method and the unit dosage form comprising said composition,
KR101535586B1 (en) * 2014-08-01 2015-07-09 에스케이케미칼주식회사 Pharmaceutical preparation comprising amorphous or metastable form of rivaroxaban
KR101806004B1 (en) * 2015-01-30 2017-12-08 씨제이헬스케어 주식회사 A pharmaceutical composition comprising candesartan and amlodipine
CN106668016B (en) * 2015-11-11 2020-06-23 江苏先声药业有限公司 Solid preparation of azilsartan and amlodipine besylate composition and preparation method thereof
JP2017210435A (en) * 2016-05-25 2017-11-30 ダイト株式会社 Method for producing irbesartan and amlodipine besylate-containing tablet
JP2019001782A (en) * 2017-06-14 2019-01-10 東和薬品株式会社 Bilayer tablet
JP7101464B2 (en) * 2017-09-28 2022-07-15 エルメッド株式会社 A method for improving the quality of azilsartan or a salt thereof and amlodipine or a salt-containing tablet thereof, and azilsartan or a salt thereof and amlodipine or a salt-containing tablet thereof and a method for producing the same.
CN108210472A (en) * 2017-12-15 2018-06-29 蚌埠丰原医药科技发展有限公司 A kind of Cilnidipine solid dispersions tablet and preparation method thereof
CN108685925B (en) * 2018-05-15 2019-12-06 徐州医科大学 application of compound AB-38b in preparation of medicine for treating diabetic nephropathy
JP2020075869A (en) * 2018-11-05 2020-05-21 日本ケミファ株式会社 Tablet containing angiotensin ii receptor antagonist and calcium antagonist as active ingredients
JP2020090471A (en) * 2018-12-07 2020-06-11 ニプロ株式会社 Pharmaceutical composition containing azilsartan and amlodipine and method for producing the same
JP7206872B2 (en) * 2018-12-07 2023-01-18 ニプロ株式会社 Pharmaceutical composition containing azilsartan and amlodipine and method for producing the same
JP7441105B2 (en) * 2020-03-31 2024-02-29 日本ジェネリック株式会社 Film-coated tablets containing azilsartan and amlodipine besilate

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2814513B2 (en) * 1988-02-03 1998-10-22 吉富製薬株式会社 Pharmaceutical composition with improved dissolution
JP3057471B2 (en) * 1993-06-07 2000-06-26 武田薬品工業株式会社 Agent for preventing or treating angiotensin II-mediated diseases
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
WO2002006234A1 (en) 2000-07-17 2002-01-24 Takeda Chemical Industries, Ltd. Sulfone derivatives, process for their production and use thereof
WO2002074340A1 (en) * 2001-03-16 2002-09-26 Takeda Chemical Industries, Ltd. Process for producing sustained release preparation
EP1452176A4 (en) * 2001-12-03 2009-01-21 Takeda Pharmaceutical Insulin resistance improving agents
AU2003235395A1 (en) * 2002-05-22 2003-12-02 Shionogi And Co., Ltd. Pharmaceutical preparation improved in dissolving property of drug slightly soluble in water
AU2003284596A1 (en) 2002-11-22 2004-06-18 Takeda Pharmaceutical Company Limited Imidazole derivative, process for producing the same, and use
US7534887B2 (en) 2003-09-30 2009-05-19 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
US7820673B2 (en) 2003-12-17 2010-10-26 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same, and use
TWI396686B (en) 2004-05-21 2013-05-21 Takeda Pharmaceutical Cyclic amide derivative, and its production and use
JP2006321726A (en) * 2005-05-17 2006-11-30 Sysmex Corp Method for controlling elution property of tablet
JP5063370B2 (en) * 2005-06-27 2012-10-31 第一三共株式会社 Method for preparing wet granulated pharmaceutical
ES2404939T3 (en) * 2005-06-27 2013-05-29 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin II receptor antagonist and a calcium channel blocker
DE102005031577A1 (en) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmaceutical dosage forms containing a combination of nifedipine and / or nisoldipine and an angiotensin II antagonist
CN101652139A (en) * 2007-03-29 2010-02-17 第一三共株式会社 Pharmaceutical composition
TW201014850A (en) * 2008-09-25 2010-04-16 Takeda Pharmaceutical Solid pharmaceutical composition

Also Published As

Publication number Publication date
BRPI1014388A2 (en) 2016-04-05
SG175794A1 (en) 2011-12-29
CN102481248B (en) 2013-12-11
CA2760073A1 (en) 2010-11-04
CL2011002662A1 (en) 2012-06-15
ZA201108375B (en) 2013-01-30
EP2424501A2 (en) 2012-03-07
AU2010242308A1 (en) 2011-12-01
WO2010126168A2 (en) 2010-11-04
TW201041873A (en) 2010-12-01
DOP2011000329A (en) 2011-11-15
GEP20135940B (en) 2013-10-10
KR20120026060A (en) 2012-03-16
IL215962A0 (en) 2012-01-31
KR101797776B1 (en) 2017-11-14
WO2010126168A3 (en) 2011-03-03
JP2012525323A (en) 2012-10-22
MX2011011011A (en) 2011-11-02
CN102481248A (en) 2012-05-30
CR20110581A (en) 2012-01-19
ECSP11011494A (en) 2011-12-30
TWI438201B (en) 2014-05-21
MA33280B1 (en) 2012-05-02
CO6470841A2 (en) 2012-06-29
MY158158A (en) 2016-09-15
EA201171329A1 (en) 2012-05-30
JP5666471B2 (en) 2015-02-12
NZ596395A (en) 2013-06-28

Similar Documents

Publication Publication Date Title
PE20120315A1 (en) A PHARMACEUTICAL COMPOSITION INCLUDING CANDESARTAN, CANDESARTAN CILEXETIL, OR AZILSARTAN, COMBINED WITH AMLODIPINE
PE20120018A1 (en) PHARMACEUTICAL COMPOSITION OF LINAGLIPTIN AND 1-CHLORINE-4- (B-D-GLUCOPYRANES-1-IL) -2- [4 - ((S) -TETRAHYDROFURAN-3-ILOXI) -BENZYL] -BENZENE, PHARMACEUTICAL FORM AND PROCEDURE FOR ITS PREPARATION
NZ594597A (en) Substituted piperidines as ccr3 antagonists
CL2011000625A1 (en) Solid preparation comprising 2-ethoxy-1 - ((2 '- (5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) biphenyl-4-yl) methyl) -1h-benzimidazole (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl carboxylate, a ph regulating agent and a calcium antagonist compound; and methods for using and improving dissolution of the compound in the solid preparation.
AR067390A1 (en) IMISMAZED TRISUSTITUTES, A PROCESS FOR THEIR DEVELOPMENT, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATIONED BY THE ANTAGONISM OF CCR RECEPTORS
PE20142448A1 (en) N-ALKYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS
AR065850A1 (en) SOLID PHARMACEUTICAL COMPOSITION INCLUDING A BENZIMIDAZOL-7-CARBOXYLATE DERIVATIVE AND A PH CONTROL AGENT
CL2009000394A1 (en) Compounds derived from substituted n- (1h-indazol-5-yl) pyrrolidin-3-carboxamide, erk inhibitors; pharmaceutical composition; and its use in the treatment of cancer.
PE20140934A1 (en) DERIVATIVES OF PIRAZOLE
ATE483707T1 (en) 2-CYCLOPROPYLTHIAZOLE DERIVATIVES
UY31863A (en) DRUG COMBINATIONS UNDERSTANDING A DGAT INHIBITOR AND A PPAR AGONIST
PE20080927A1 (en) BENZOIL-AMINO-HETEROCYCLYL DERIVATIVES AS GLUCOKINASE (GLK) ACTIVATORS
PE20142301A1 (en) URACILOS BICYCLICALLY REPLACED AND USE OF THE SAME
PE20081315A1 (en) BENZIMIDAZOLE DERIVATIVES AS ANTAGONISTS OF VR-1
CO6761298A2 (en) Combinations comprising atypical antipsychotics and taar1 antagonists
CO6400144A2 (en) AMINOESTER DERIVATIVES OF ALCALOIDS AND MEDICINAL COMPOSITION OF THE SAME
CL2011003371A1 (en) Solid and stable oral fixed dose pharmaceutical composition comprising irbesartan, amlodipine besilate and excipients; preparation procedures; use in the treatment of hypertension.
AR076300A1 (en) DERIVATIVES OF PIRIMIDIN REPLACED IMIDAZOLS, INHIBITORS OF GSK3, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USES OF THE SAME IN THE TREATMENT OF ALZHEIMER, ACUTE NEURODEGENERATIVE DISEASES, DIABETES AND OTHER DISEASES.
PE20090654A1 (en) GALENIC FORMULATIONS CONTAINING ALISQUIREN AND VALSARTAN
CR20110093A (en) [4- (5-aminomethyl-2-fluoro-phenyl) -piperidin-1-yl] - [7-fluoro-1- (2-methoxy-ethyl) -4-trifluoromethoxy-1h-indole-3-yl] - methanone as a mast cell tryptase inhibitor
AR065714A1 (en) CHLORHYDRATE SALT OF 5- (3- (3- HYDROXYPHENOXY) AZETIDIN- 1 - IL) - 5 - METHYL - 2, 2 - DIFENYLHEXANAMIDE
PL2021002T3 (en) Pharmaceutical composition comprising olmesartan medoxomil
CO6321246A2 (en) ACTIVE NEW NOVEDOUS COMPOUNDS AS MUSCARINIC RECEIVER ANTAGONISTS
PE20091718A1 (en) (PIRAZOLYLCARBONIL) IMIDAZOLIDINONES SUBSTITUTED WITH ANTIVIRAL ACTIVITY
PE20110551A1 (en) SOLID PHARMACEUTICAL COMPOSITION CONTAINING A BENZIMIDAZOLE DERIVATIVE AND A DIURETIC

Legal Events

Date Code Title Description
FC Refusal